ArticleFrontiers in oncology2026
Efficacy and safety of disitamab vedotin in treatment of advanced gastric cancer based on real-world.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of disitamab vedotin (RC48) in the treatment of advanced gastric cancer in real-world. Methods: A retrospective analysis was conducted on clinical data of patients with human epidermal growth factor receptor 2 (HER2)-expressing advanced gastric cancer who were treated with disitamab vedotin at our institution between October 2021 and October 2024. Clinical efficacy and adverse events were assessed. Factors influencing the efficacy of disitamab vedotin were evaluated using the Log-rank test for intergroup analysis. Results: A total of 58 patients with HER2-expressing advanced gastric cancer who received RC48 treatment were included in this study. The objective response rate (ORR) was 10.3%, and the disease control rate (DCR) was 63.8%. The median progression-free survival (mPFS) for all patients was 4.2 months (95% CI = 3.002-5.398), with a 1-year progression-free survival rate of 13.0%. Subgroup analysis revealed that DCR was significantly higher in patients receiving RC48 as third-line therapy compared to those receiving it as later-line therapy (75.0% Conclusions: In the real-world setting, RC48 shows some clinical efficacy and a manageable safety profile in patients with HER2-expressing advanced gastric cancer. These findings provide useful information for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.